– Successful outcome from FDA meeting on ALTO-207 in treatment-resistant depression; on track to initiate Phase 2b trial in the first half of 2026 and Phase 3 trial by early 2027 – ...
Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that...
– Financing led by Perceptive Advisors with participation from new and existing biotech focused investors – – Alto expects to use the proceeds of this financing...
– Successful outcome from recent FDA meeting guides Alto’s plan to accelerate development of ALTO-207, with capital from a $50 million private placement financing expected to enable the company to...
– ALTO-101, a novel PDE4 inhibitor, has demonstrated pro-cognitive effects in healthy volunteers – – Designation highlights the significant unmet need for new treatments...
SAN DIEGO , Sept. 19, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired (a) Alto Neuroscience,...
NEW YORK , Sept. 19, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Alto Neuroscience, Inc. ("Alto Neuroscience, Inc." or the "Company") (NYSE: ANRO) of a class action...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Alto To Contact Him Directly To Discuss...
New York, New York--(Newsfile Corp. - September 18, 2025) - If you suffered a loss on your Alto Neuroscience, Inc. (NYSE: ANRO) investment and want to learn about a potential recovery under the federal...
NEW YORK , Sept. 18, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Alto Neuroscience, Inc. ("Alto" or the "Company") (NYSE: ANRO) and...